These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1318685)

  • 1. Antibacterial activity of sparfloxacin against experimental renal infections in mice.
    Georgopoulos A; Feistauer SM; Graninger W; Pfleger S; Georgopoulos M
    Antimicrob Agents Chemother; 1992 Feb; 36(2):505-7. PubMed ID: 1318685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
    Cagni A; Chuard C; Vaudaux PE; Schrenzel J; Lew DP
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1655-60. PubMed ID: 7486895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro activity of sparfloxacin against methicillin-resistant staphylococci].
    Wallrauch C; Voss A; Milatovic D; Braveny I
    Arzneimittelforschung; 1995 Jun; 45(6):723-5. PubMed ID: 7646580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent.
    Guinea J; Robert M; Gargallo-Viola D; Xicota MA; Garcia J; Tudela E; Esteve M; Coll R; Pares M; Roser R
    Antimicrob Agents Chemother; 1993 Apr; 37(4):868-74. PubMed ID: 8388202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of sparfloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection.
    Naber KG; di Silverio F; Geddes A; Guibert J
    J Antimicrob Chemother; 1996 May; 37 Suppl A():135-44. PubMed ID: 8737133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
    Barry AL; Fuchs PC
    Antimicrob Agents Chemother; 1991 May; 35(5):955-60. PubMed ID: 1906696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative activities of norfloxacin and fleroxacin in experimental infections due to Salmonella typhimurium and Escherichia coli.
    Hof H; Fabrig J
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():123-7. PubMed ID: 3144530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sparfloxacin therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.
    Maserati R; Cagni AE; Segú C
    Chemotherapy; 1996; 42(2):133-9. PubMed ID: 8697888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.
    Brook I
    Antimicrob Agents Chemother; 1993 May; 37(5):997-1000. PubMed ID: 8517727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal elimination of sparfloxacin, fleroxacin, and ciprofloxacin in rats.
    Rubinstein E; Dautrey S; Farinoti R; St Julien L; Ramon J; Carbon C
    Antimicrob Agents Chemother; 1995 Jan; 39(1):99-102. PubMed ID: 7695338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of sparfloxacin and autoradiographic diffusion pattern of [14C]Sparfloxacin in experimental Staphylococcus aureus joint prosthesis infection.
    Crémieux AC; Mghir AS; Bleton R; Manteau M; Belmatoug N; Massias L; Garry L; Sales N; Mazière B; Carbon C
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2111-6. PubMed ID: 8878590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs.
    Lautzenhiser SJ; Fialkowski JP; Bjorling D; Rosin E
    Res Vet Sci; 2001 Jun; 70(3):239-41. PubMed ID: 11676620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative therapeutic efficacy of clinafloxacin in leucopenic mice.
    Shapiro MA; Dever JA; Sesnie JC; VanderRoest SR
    J Antimicrob Chemother; 1997 Feb; 39(2):273-6. PubMed ID: 9069553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Lamp KC; Bailey EM; Rybak MJ
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1192-7. PubMed ID: 1329613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study Group.
    Henry DC; Nenad RC; Iravani A; Tice AD; Mansfield DL; Magner DJ; Dorr MB; Talbot GH
    Clin Ther; 1999 Jun; 21(6):966-81. PubMed ID: 10440621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
    Antimicrob Agents Chemother; 1989 Apr; 33(4):519-21. PubMed ID: 2499251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
    Kim JH; Choi KH; Kim JW; Lee JH; Choi EC; Kim BK
    J Antimicrob Chemother; 1998 Feb; 41(2):223-9. PubMed ID: 9533464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
    Cormican MG; Jones RN
    J Antimicrob Chemother; 1995 Aug; 36(2):431-4. PubMed ID: 8522474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
    Fernandes PB; Chu DT; Bower RR; Jarvis KP; Ramer NR; Shipkowitz N
    Antimicrob Agents Chemother; 1986 Feb; 29(2):201-8. PubMed ID: 3521473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative therapeutic efficacy of clinafloxacin in a Pseudomonas aeruginosa mouse renal abscess model.
    Shapiro MA; Sesnie JC; Desaty TM; Griffin TJ; Heifetz CL
    J Antimicrob Chemother; 1998 Mar; 41(3):403-5. PubMed ID: 9578169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.